Adjunctive hyperbaric oxygen therapy with reconstruction of lower eyelid for basal cell carcinoma: A case series
International Journal of Surgery Case Reports, ISSN: 2210-2612, Vol: 103, Page: 107890
2023
- 1Citations
- 8Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- CrossRef1
- Captures8
- Readers8
- Mentions1
- News Mentions1
- 1
Most Recent News
University Sam Ratulangi Reports Findings in Basal Cell Cancer (Adjunctive hyperbaric oxygen therapy with reconstruction of lower eyelid for basal cell carcinoma: A case series)
2023 FEB 01 (NewsRx) -- By a News Reporter-Staff News Editor at Chemicals & Chemistry Daily -- New research on Oncology - Basal Cell Cancer
Article Description
Basal cell carcinoma (BCC) is among the most widespread non-melanoma skin cancers, with an incidence of around 80 % worldwide. Surgery is the main therapy of choice. High-pressure oxygen is used in hyperbaric oxygen therapy (HBO) to treat hypoxic tissue conditions. By using this technique, the tissue oxygen tensions increase. This is used to treat a wide range of diseases and disorders brought on by hypoxic states, circulation issues, inadequate tissue oxygenation due to vascular damage, tissue damage from infections or accidents, and impairment of tissue healing. This paper presents five cases of HBO used in the healing BCC surgery. All patients underwent wide and deep excisions with eight adjunctive sessions of HBO therapy. The five cases of post-surgery wound healing improved significantly with HBO. BCC is a condition that is frequently identified in the outpatient department. Prerequisites for a better prognosis include early diagnosis based on sound information and prompt, structured, and sufficient therapy. Our study reveals the benefit of HBO in increasing wound healing and preventing complications after surgery for BCC.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2210261223000184; http://dx.doi.org/10.1016/j.ijscr.2023.107890; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85146282801&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36642024; https://linkinghub.elsevier.com/retrieve/pii/S2210261223000184; https://dx.doi.org/10.1016/j.ijscr.2023.107890
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know